Allergy Therapeutics updates on progress at international event
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) is set to present its latest research at the 2025 American Academy of Allergy, Asthma…
0,081€
9,52%
Echtzeit-Aktienkurs Allergy Therapeutics PLC
Bid:
Ask:
Nachrichten zur Allergy Therapeutics PLC Aktie
Allergy Therapeutics hails key validation of grass allergy treatment
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) says the latest publication of phase III trial data provides important validation of its treatment,…
Allergy Therapeutics building momentum as sales and volumes recover
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) said it is back on track and growing again after the financial and operational challenges of…
Allergy Therapeutics: A story of resilience and transformation
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) is writing a story of resilience and transformation. Putting behind it manufacturing setbacks, the company has...…
Allergy Therapeutics unveils encouraging early data from peanut trial
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) has announced encouraging interim findings from its phase I/IIa VLP Peanut PROTECT trial aimed at…
Allergy Therapeutics begins paediatric trial for grass allergy treatment
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) has commenced a phase III trial to test the long-term safety and effectiveness of its…
Allergy Therapeutics applies for full marketing approval for grass allergy jab
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) marked a significant milestone after it applied for regulatory approval of its new grass allergy...…
Global Allergy Therapeutics Market Size To Exceed USD 42.5 Billion By 2033 | CAGR Of 6.29%
The Global Allergy Therapeutics Market Size was Valued at USD 23.1 Billion in 2023 and the Worldwide Allergy Therapeutics Market…